The purpose of this study is to evaluate an investigational drug called AV-101 in patients with pulmonary arterial hypertension (PAH). Researchers aim to determine the effects of AV-101 on people with PAH over a longer period of time. This study is a long-term extension study of people who completed another study (AV-101-002), a 24-week study of AV-101 in people with PAH. AV-101 is an investigational dry powder of imatinib that is inhaled into the lungs via the mouth. Imatinib is involved in blocking enzymes that may activate proteins that cause the pulmonary arteries to thicken, making it difficult for blood to flow between the lungs and the heart. All participants in this study will receive AV-101 treatment.
What is the full name of this clinical trial?
IMPAHCT-FUL : A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension Who Have Completed Study AV-101-002.